HomeInsightsStock Comparison

Advanced Enzyme Technologies Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Advanced Enzyme Technologies Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Last Updated on: Sep 09, 2025

Key Highlights

  • The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 342.4 as of 09 Sep 15:30.
  • The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 12.4 on March 2020 to 23.8 on March 2025 . This represents a CAGR of 11.48% over 6 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 41.5 on March 2025 . This represents a CAGR of 32.99% over 6 years.
  • The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 1598 crore on March 2020 to ₹ 3120 crore on March 2025 . This represents a CAGR of 11.79% over 6 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 43458 crore on March 2025 . This represents a CAGR of 39.83% over 6 years.
  • The revenue of Advanced Enzyme Technologies Ltd for the Jun '25 is ₹ 194.76 crore as compare to the Mar '25 revenue of ₹ 175.92 crore. This represent the growth of 10.71% The revenue of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 3290 crore as compare to the Mar '25 revenue of ₹ 3267 crore. This represent the growth of 0.7%.
  • The ebitda of Advanced Enzyme Technologies Ltd for the Jun '25 is ₹ 65.28 crore as compare to the Mar '25 ebitda of ₹ 54.35 crore. This represent the growth of 20.11% The ebitda of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 283.73 crore as compare to the Mar '25 ebitda of ₹ 199.89 crore. This represent the growth of 41.94%.
  • The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 29.38 crore to ₹ 40.44 crore over 9 quarters. This represents a CAGR of 15.26% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 46.97 crore over 9 quarters. This represents a CAGR of -44.00% .
  • The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 11.56 % on March 2020 to 56.81 % on March 2025 . This represents a CAGR of 30.39% over 6 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 4.38 % on March 2025 . This represents a CAGR of -2.85% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Advanced Enzyme Technologies Ltd

  • Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
  • The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
  • It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

Advanced Enzyme Technologies Ltd News Hub

News

Advanced Enzyme Technologies Ltd leads gainers in 'A' group

Relaxo Footwears Ltd, Apollo Micro Systems Ltd, Granules India Ltd and Godfrey Phillips In...

Read more

29 Aug 2025 12:00

News

Advanced Enzyme Technologies Ltd leads losers in 'A' group

Shakti Pumps (India) Ltd, Neogen Chemicals Ltd, Balaji Amines Ltd and Thermax Ltd are amon...

Read more

04 Aug 2025 15:00

News

Advanced Enzyme Techs. to announce Quarterly Result

Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 2 A...

Read more

26 Jul 2025 10:03

News

Board of Advanced Enzyme Techs. recommends final dividend

Advanced Enzyme Techs. announced that the Board of Directors of the Company at its meeting...

Read more

13 May 2025 14:29

News

Board of Advanced Enzyme Techs. recommends interim dividend

Advanced Enzyme Techs. announced that the Board of Directors of the Company at its meeting...

Read more

13 May 2025 14:29

News

Advanced Enzyme Techs. to convene AGM

Advanced Enzyme Techs. announced that the 36th Annual General Meeting(AGM) of the company ...

Read more

13 May 2025 17:04

Glenmark Pharmaceuticals Ltd News Hub

News

Ichnos Glenmark Innovation receives upfront payment of USD700 million

Ichnos Glenmark Innovation (IGI), Glenmark's wholly owned subsidiary, has received an upfr...

Read more

09 Sep 2025 09:06

News

Glenmark Pharma initiates Phase 3 clinical trial for Envafolimab

Glenmark Pharmaceuticals announced the initiation of a multi-country (ex-China) Phase 3 Cl...

Read more

05 Sep 2025 09:54

News

Glenmark Pharma's US arm to launch Eribulin Mesylate injection in the US market

The product is the therapeutic equivalent of Halaven Injection (1 mg/2 mL), originally dev...

Read more

02 Sep 2025 12:32

News

Glenmark USA to launch Eribulin Mesylate Injection, mg/2 mL (0.5 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Eribulin Me...

Read more

02 Sep 2025 13:02

News

Glenmark Pharmaceuticals to conduct AGM

Glenmark Pharmaceuticals announced that the Annual General Meeting(AGM) of the company wil...

Read more

23 Aug 2025 11:07

News

Glenmark USA to launch Micafungin for Injection 50 mg/vial and 100 mg/vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin ...

Read more

19 Aug 2025 10:07

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Advanced Enzyme Technologies Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Advanced Enzyme Technologies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,830 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 59,720 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd?

As of September 9, 2025, the Advanced Enzyme Technologies Ltd stock price is INR ₹342.4. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2116.25.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions